[go: up one dir, main page]

CA2363847A1 - Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines - Google Patents

Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines Download PDF

Info

Publication number
CA2363847A1
CA2363847A1 CA002363847A CA2363847A CA2363847A1 CA 2363847 A1 CA2363847 A1 CA 2363847A1 CA 002363847 A CA002363847 A CA 002363847A CA 2363847 A CA2363847 A CA 2363847A CA 2363847 A1 CA2363847 A1 CA 2363847A1
Authority
CA
Canada
Prior art keywords
phenylalanine
ribose
blood pressure
administering
hypertensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002363847A
Other languages
English (en)
Inventor
Kenneth Blum
Seymour Ehrenpreis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363847A1 publication Critical patent/CA2363847A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une nouvelle catégorie d'agents efficaces contre l'hypertension: ces produits inhibent la destruction des substances endogènes, à savoir les enképhalines ou les endorphines. L'action hypotensive d'un inhibiteur de ces substances est considérablement améliorée si on combine le produit avec un bêtabloquant. Spécifiquement, la D-phénylalanine est un inhibiteur du type considéré, si on l'utilise seule, et cet inhibiteur donne d'excellents résultats quant à la réduction de la pression sanguine chez l'animal et l'homme. La combinaison de D-phénylalanine et de propranolol bêtabloquant améliore considérablement l'action hypotensive chez le rat spontanément hypertendu. La réduction de la pression sanguine par administration de D-phénylalanine, ou par administration de la combinaison susmentionnée, a un effet très durable chez le rat spontanément hypertendu et chez l'homme. Si la pression sanguine chez le rat et chez l'homme est normale, la D-phénylalanine produit un effet réduit ou bien est inopérante sur la pression sanguine. On prévient l'action hypotensive de ce produit en effectuant chez le rat spontanément hypotendu un prétraitement à base de naloxone et de naltrexone, ces deux substances étant des antagonistes spécifiques vis-à-vis des enképhalines ou des endorphines.
CA002363847A 1999-01-12 2000-01-12 Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines Abandoned CA2363847A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11572499P 1999-01-12 1999-01-12
US60/115,724 1999-01-12
PCT/US2000/000722 WO2000041686A1 (fr) 1999-01-12 2000-01-12 Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines

Publications (1)

Publication Number Publication Date
CA2363847A1 true CA2363847A1 (fr) 2000-07-20

Family

ID=22363061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363847A Abandoned CA2363847A1 (fr) 1999-01-12 2000-01-12 Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines

Country Status (4)

Country Link
EP (1) EP1158972A4 (fr)
AU (1) AU2502700A (fr)
CA (1) CA2363847A1 (fr)
WO (1) WO2000041686A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60333628D1 (de) * 2002-05-14 2010-09-16 Nipro Corp Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
US9937146B2 (en) 2016-03-23 2018-04-10 Bioadatp, Llc Enkephalin-influencing composition and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD229931A1 (de) * 1984-11-09 1985-11-20 Adw Ddr Verfahren zur herstellung eines mittels mit antistresswirkung
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5420271A (en) * 1992-08-24 1995-05-30 Merrell Dow Pharmaceuticals, Inc. 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5425954A (en) * 1993-09-30 1995-06-20 Curafas Incorporated Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use
GB2286528B (en) * 1994-02-17 1998-09-16 Robert John Woodward Dietary supplement

Also Published As

Publication number Publication date
AU2502700A (en) 2000-08-01
EP1158972A4 (fr) 2003-05-02
EP1158972A1 (fr) 2001-12-05
WO2000041686A1 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
EP1908461B9 (fr) Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament
Ewis et al. Effect of metformin on glutathione and magnesium in normal and streptozotocin‐induced diabetic rats
US6955873B1 (en) Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
US20060211721A1 (en) Nutraceutical formulation of a cognitive enhancement system
EP2305225A1 (fr) Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament
EP0329879B1 (fr) Amino-acides utiles contre les troubles hépatiques
WO2006069293A2 (fr) Composition pour traitement de la douleur
JP2002542191A (ja) グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物
CN105943530B (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
Rand et al. The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors
AU750645B2 (en) Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH
Rauhut et al. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration
CA2363847A1 (fr) Traitement de l'hypertension avec des composes inhibant la destruction des enkephalines ou des endorphines
Katz et al. Neurohumoral mechanisms in the brain slice
AU2004242565A1 (en) Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
JP2022544718A (ja) 敗血症性心筋症を治療するための組成物および方法
Pouchelon et al. Effects of clomipramine hydrochloride on heart rate and rhythm in healthy dogs
Hacker Inhibition of deoxyribonucleic acid synthesis by difluoromethylornithine: role of polyamine metabolism in monocrotaline-induced pulmonary hypertension
US20060094765A1 (en) Use of a sri and vitamin b6 for the treatment of neurological and mental disorders
Tabei et al. Antihypertensive and noradrenaline-depleting effects of α-methyl-5-hydroxytryptophan in the rat
Ruotsalainen et al. Taurine infused intrastriatally elevates, but intranigrally decreases striatal extracellular dopamine concentration in anaesthetised rats
Vallance et al. Nitric oxide and hypertension: physiology and pathophysiology
Hui et al. EFFECTS OF CHRONIC NICOTINE INGESTION ON PRESSOR RESPONSE TONω-NE2RO-L-ARGININE METHYL ESTER ANDEX VIVOCONTRACTION AND RELAXATION RESPONSE OF AORTA TOL-ARGININE
US20060105965A1 (en) Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations

Legal Events

Date Code Title Description
FZDE Discontinued